ABC | Volume 111, Nº2, August 2018

Minieditorial Minicucci e Zornoff VEGFR-2: uma das vias de sinalização da pioglitazona no coração Arq Bras Cardiol. 2018; 111(2):170-171 1. de Pablos-Velasco P. Pioglitazone: beyond glucose control. Expert Rev Cardiovasc Ther. 2010;8(8):1057-67. 2. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary. Endocr Pract. 2018;24(1):91-120. 3. Vaccaro O, Masulli M, Riccardi G. Glucose lowering strategies and cardiovascular disease in type 2 diabetes – teachings from the TOSCA.IT study. Nutr Metab Cardiovasc Dis. 2018;28(7):722-6. 4. ZinmanB,WannerC,LachinJM,FitchettD,BluhmkiE,HantelS,etal;EMPA- REGOUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-28. 5. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, NauckMA, et al; LEADER trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. 6. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. SUSTAIN-6 investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375(19):1834-44. 7. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-57. 8. American Diabetes Association. 8 Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes – 2018. Diabetes Care. 2018;41(Suppl 1):S73-85. 9. Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, et al; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT) : a randomized multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887-97. Erratum in: Lancet Diabetes Endocrinol. 2017;5(11):e7. 10. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomized controlled trial. Lancet. 2005;366(9493):1279-89. 11. Nissen SE, Nicholls SJ,Wolski K, Nesto R, Kupfer S, Perez A, et al; PERISCOPE investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561-73. 12. Khodeer DM, Zaitone SA, Farag NE, Moustafa YM. Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE-RAGE axis and inhibition of apoptosis. Can J Physiol Pharmacol. 2016;94(5):463-76. 13. Chang CS, Tsai PJ, Sung JM, Chen JY, Ho LC, Pandya K, et al. Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice. Am J Pathol. 2014;184(2):442-53. 14. Wei WY, Zhang N, Li LL, Ma ZG, XuM, Yuan YP, et al. Pioglitazone alleviates cardiac fibrosis and inhibits endothelial tomesenchymal transition induced by pressure overload. Cell Physiol Biochem. 2018;45(1):26-36. 15. Zhong W, Jin W, Xu S, Wu Y, Luo S, Liang M, et al. Pioglitazone induces cardiomyocyteapoptosisandinhibitscardiomyocytehypertrophyviaVEGFR-2 signaling pathway. Arq Bras Cardiol. 2018; 111(2):162-169. References This is an open-access article distributed under the terms of the Creative Commons Attribution License 171